IN Brief:
- DHL launched six dedicated life-sciences air freight corridors into Asian hubs on 12 October.
- Network aircraft, validated handling and thermal solutions aim to reduce temperature excursions and unnecessary handovers.
- DHL has announced investment in specialist cold-chain infrastructure in Singapore and additional refrigerated capacity at Indianapolis.
DHL Global Forwarding has added six dedicated pharmaceutical air freight corridors connecting Europe and North America with major healthcare markets in Asia, extending its temperature-controlled transport network to Shanghai, Singapore, Tokyo and Seoul. Announced on 12 October, the expansion is designed to improve route choice and cargo handling for pharmaceuticals, biologics, vaccines and other healthcare products whose quality can depend on remaining within specified temperature conditions throughout transit.
The new corridors are Liège–Shanghai, Brussels–Shanghai, Brussels–Singapore, Cincinnati–Singapore, Cincinnati–Tokyo Narita and Cincinnati–Seoul Incheon. Together they connect established European and United States air freight gateways with manufacturing, research and distribution centres across East and South-East Asia. They also broaden the reach of DHL’s Cold Chain Network following the launch of a dedicated Brussels–Cincinnati corridor earlier this year.
Dedicated corridors give DHL a more defined sequence of airline, warehouse and ground-handling arrangements across the expanded network. A pharmaceutical shipment may pass through warehouses, aircraft loading areas, ground handlers and transfer points before reaching its consignee. Each change of custody can complicate temperature monitoring and create another occasion when freight is exposed to conditions outside its prescribed range. A network built around dedicated corridors attempts to make those processes more predictable.
DHL says most of the flights supporting the new services will operate on aircraft in its own network. The company uses Boeing 777 freighters with three compartments offering separate temperature settings, allowing air transport to be organised around the differing needs of sensitive cargo. This does not mean every shipment across all six corridors uses the same temperature regime, or that the aircraft alone provides sufficient product protection. Handling procedures before loading and after unloading remain part of the service.
The operational model combines validated procedures with temperature-control measures including thermal blankets and phase-change materials. Such materials can help moderate exposure while shipments are in transit or undergoing transfers, complementing controlled storage and airport handling. Their selection and application depend on the required temperature band, journey length and packaging specification. DHL has presented the system as a way to reduce temperature excursions, but has not disclosed corridor-by-corridor performance figures in the October announcement.
The corridors establish specific new links and handling arrangements, but DHL has not provided measurements of actual temperature excursions or changes in transit times and costs on the new routes. Shipment records will be needed to compare those outcomes with existing transport options, particularly where consignments have to change aircraft or handling teams.
Singapore occupies a central position in the expansion. Brussels–Singapore and Cincinnati–Singapore create two dedicated links to a regional healthcare logistics gateway, where DHL has already announced further investment. A planned Singapore Cold Chain Hub is intended to provide storage and handling areas for products requiring 2–8°C and 15–25°C conditions, together with direct airside access. Refrigerated and controlled ambient medicines need different storage conditions, so the new hub’s planned areas would support more than one validated temperature regime.
The North American side also extends beyond the Cincinnati airport. DHL is expanding its life-sciences and healthcare facility in Indianapolis, approximately two and a half hours by road from the Cincinnati gateway, with additional refrigerated operational and pallet storage space. Linking airport capacity with nearby specialist logistics sites can support consolidation and onward distribution, provided road transfers, storage and aircraft departures remain coordinated.
Dedicated corridors can reduce reliance on ad hoc arrangements at intermediate airports, although qualified packaging remains necessary for individual products. Route selection will still involve trade-offs between uplift frequency, delivery requirements, approved handling processes and the capabilities available at both ends of the movement. Some products require stricter controls than others, while clinical trial material may present different scheduling needs from routine commercial replenishment. Product-specific packaging arrangements must still satisfy qualification requirements; manufacturers remain responsible for establishing the transport conditions suitable for each shipment profile.
The new routes rely on coordination between aircraft capacity, temperature-controlled facilities and the teams responsible for handling each shipment. Network ownership and temperature-controlled facilities are valuable only when accompanied by consistent operating processes, verified shipment data and accountable handovers. DHL has identified the corridors and supporting infrastructure; operating records across the newly connected Asian markets will determine whether that consistency is sustained as traffic grows.
